Vor Biopharma Inc.

Equities

VOR

US9290331084

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 04:00:00 2024-04-26 pm EDT			5-day change	1st Jan Change
1.69 ^USD	-0.59%		-1.17%	-24.89%

Mar. 21	Stifel Cuts Price Target on Vor Biopharma to $12 From $15, Maintains Buy Rating	MT
Mar. 21	Oppenheimer Cuts Vor Biopharma Price Target to $15 From $18, Maintains Outperform Rating	MT

Vor Biopharma Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023

August 10, 2023 at 04:01 pm EDT

Vor Biopharma Inc. reported earnings results for the second quarter and six months ended June 30, 2023. For the second quarter, the company reported net loss was USD 29.98 million compared to USD 21.66 million a year ago. Basic loss per share from continuing operations was USD 0.45 compared to USD 0.58 a year ago.
For the six months, net loss was USD 58.41 million compared to USD 44.4 million a year ago. Basic loss per share from continuing operations was USD 0.88 compared to USD 1.19 a year ago.

Latest news about Vor Biopharma Inc.

Stifel Cuts Price Target on Vor Biopharma to $12 From $15, Maintains Buy Rating	Mar. 21	MT
Oppenheimer Cuts Vor Biopharma Price Target to $15 From $18, Maintains Outperform Rating	Mar. 21	MT
Vor Biopharma Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	Mar. 20	CI
Vor Biopharma Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 20	CI
Vor Biopharma Doses First Blood Cancer Patient With Leukemia Treatment, Provides Cash Runway Guidance	Jan. 17	MT
Vor Bio Doses First AML Patient with VCAR33	Jan. 17	CI
Vor Bio Presents Positive Data Update on Trem-cel at HSCT² Conference	Nov. 09	CI
Vor Biopharma Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 07	CI
Vor Bio Announces Multiple Clinical and Preclinical Presentations at ASH 2023 Highlight Vor Bio's Novel eHSC and CAR-T Platform	Nov. 02	CI
Wedbush Cuts Vor Biopharma's Price Target to $11 From $18, Keeps Outperform Rating	23-08-11	MT
Vor Biopharma Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-10	CI
Vor Biopharma Inc.(NasdaqGS:VOR) added to Russell Small Cap Comp Value Index	23-06-23	CI
Vor Biopharma Inc.(NasdaqGS:VOR) added to Russell 3000 Index	23-06-23	CI
Vor Biopharma Inc.(NasdaqGS:VOR) added to Russell 3000E Index	23-06-23	CI
Vor Biopharma Inc.(NasdaqGS:VOR) added to Russell Small Cap Completeness Index	23-06-23	CI
Vor Biopharma Inc.(NasdaqGS:VOR) added to Russell 2500 Index	23-06-23	CI
Vor Biopharma Inc.(NasdaqGS:VOR) added to Russell 2000 Index	23-06-23	CI
Vor Biopharma Inc.(NasdaqGS:VOR) added to Russell 3000E Value Index	23-06-23	CI
Vor Biopharma Inc.(NasdaqGS:VOR) added to Russell 3000 Value Index	23-06-23	CI
Vor Biopharma Inc.(NasdaqGS:VOR) added to Russell 2000 Value Index	23-06-23	CI
Vor Biopharma Inc.(NasdaqGS:VOR) added to Russell 2000 Dynamic Index	23-06-23	CI
Vor Biopharma Inc.(NasdaqGS:VOR) added to Russell 2500 Value Index	23-06-23	CI
Vor Biopharma Says US FDA Clears Investigational New Drug Application for Cancer Therapy	23-06-09	MT
Vor Biopharma Inc. Presents Updated Clinical Data from Patients Treated in VBP101	23-06-09	CI
JonesTrading Starts Vor Biopharma at Buy With $18 Price Target	23-05-16	MT

Chart Vor Biopharma Inc.

Duration

Period

More charts

Company Profile

Vor Biopharma Inc. is a clinical-stage cell and genome engineering therapy company. The Company is engaged in combining a novel patient engineering approach with targeted therapies to provide solutions for patients suffering from hematological malignancies. Its proprietary platform leverages expertise in hematopoietic stem cell (HSC) biology, genome engineering and targeted therapy development to genetically modify HSCs to remove surface targets expressed by cancer cells. The Companyâs lead engineered hematopoietic stem cells (eHSC) product candidate include tremtelectogene empogeditemcel (trem-cel), for the treatment for acute myeloid leukemia (AML) and other blood cancers. It is designed to replace the standard of care in transplant settings for patients suffering from acute myeloid leukemia (AML) and other blood cancers. Its VBP101 is a Phase I/II a multicenter, open-label, first-in-human study of trem-cel in patients with AML.

Sector

Biotechnology & Medical Research

Calendar

2024-04-29 - Chardans Genetic Medicines Cell Therapy Manufacturing Summit

Related indices

Russell 2000

More about the company

Income Statement Evolution

More financial data

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

1.69 USD

Average target price

14.69 USD

Spread / Average Target

+769.08%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
VOR BIOPHARMA INC.	-24.89%	115M
IQVIA HOLDINGS INC.	+1.51%	42.75B
MODERNA, INC.	+8.57%	41.34B
LONZA GROUP AG	+49.22%	41.61B
CELLTRION, INC.	-12.36%	26.59B
ICON PUBLIC LIMITED COMPANY	+8.92%	25.49B
ALNYLAM PHARMACEUTICALS, INC.	-25.13%	18.12B
MEDPACE HOLDINGS, INC.	+29.17%	12.24B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	-3.12%	11.76B
UNITED THERAPEUTICS CORPORATION	+6.35%	11B

Other Biotechnology & Medical Research